Page 2,575«..1020..2,5742,5752,5762,577..2,5802,590..»

GEN’s “Cellular Therapy Wave Finally Cresting”. An overview and data set.

Posted: November 4, 2012 at 8:01 am


We first provided a listing (with very few details) of industry-sponsored late-stage (pivotal, phase 3 and 2/3) cell therapy clinical trials on this blog late last year (see the posting here).

We are now pleased to we have worked with Genetic Engineering and Biotechnology News and Enal Razvi of Select Biosciences to provide an updated (as of June 2012) and more detailed listing of industry-sponsored late-stage (pivotal, phase 3 and 2/3) cell therapy clinical trials (excluding cell-based immunotherapies which we intend to cover in a follow-up article).

A link to the listing can be found in an article published today entitled "Cellular Therapy Wave Finally Cresting" found in the November 1, 2012 issue of GEN.  

While not my favorite title, the article is a brief - but we hope useful - overview of the sector and its pipeline.  It also provides a snapshot of the cell therapy products already in commercial distribution. 
Some will quibble about the numbers. Certainly others have published larger revenue numbers, for instance, but in our view these have almost always included revenue from cord blood banking which we have excluded.
We encourage you to read the article but for convenience here is a direct link to the spreadsheet.  Of course it's already out-dated but we'll do an update again soon here on this blog.


Hope this is useful.
--Lee


Source:
http://feedproxy.google.com/~r/CellTherapyBlog/~3/ctijFXeY01M/gens-cellular-therapy-wave-finally.html

Posted in Regenerative Medicine | Comments Off on GEN’s “Cellular Therapy Wave Finally Cresting”. An overview and data set.

Study of California Stem Agency Likely to be Released in About a Month

Posted: November 4, 2012 at 8:00 am


The $700,000, Institute of Medicine performance study of the $3 billion California stem cell agency is expected to be
released in late November or early December, the IOM said today.

In response to a question last week
from the California Stem Cell Report, Christine Stencel, senior media
relations officer for the IOM in Washington, D.C., briefly discussed
the release plans and the impact of the East Coast super-storm.
Here is the text of her response:

“The DC area escaped the worst of
Sandy’s thumping but nonetheless our schedules and planning have
been somewhat thrown off as we’re playing catch up after two days
of being shut down and some of our committee members and reviewers
are in the areas that got the brunt of the storm. We’re not sure
whether the storm will cause any delays in peer review, but we’re
working toward the goal of publicly releasing the report in late
November or early December. The study staff is working with committee
members to determine the best release format but I anticipate there
will be a press briefing. I’ll send a media advisory when we’ve
got all the details worked out.”

The stem cell agency is paying for the
report, which is examining the performance of the agency. The IOM
began its work in the summer of 2011.

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/iNEFrnWvUO0/study-of-california-stem-agency-likely.html

Posted in Stem Cells, Stem Cell Therapy | Comments Off on Study of California Stem Agency Likely to be Released in About a Month

Geron Weighs Biotime Bid for hESC Biz

Posted: November 4, 2012 at 8:00 am


Geron, Inc., of Menlo Park, Ca., said
today it is assessing an offer by two of its former executives to buy
the human embryonic stem cell program that it abandoned nearly a year
ago.
Geron startled the stem cell world,
including the $3 billion California stem cell agency, when it
jettisoned the first clinical trial of an hESC therapy for financial
reasons. The agency had loaned the company $25 million just a few
months earlier. Geron repaid the loan with interest.
Geron has been mum until today about the Oct. 18 offer by Biotime, Inc., of Alameda, Ca., which is headed
by Michael West, who founded Geron in 1990. Tom Okarma, president of
Geron from 1999 to 2011, is involved with West on the deal and is now
working at Biotime.
Geron's remarks came during a
conference call on its third quarter earnings. A spokesman said the
company is working with Biotime to “assess the feasibility” of
the proposal. He said the proposed transaction is complex and the
company is seeking “additional important details.”
The spokesman declined to offer any
additional comments on the Biotime proposal when questioned following
his initial statement.  
See here and here for earlier stories on the California Stem Cell Report on the Biotime offer. 

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/4JnJvoKwHpA/geron-weighs-biotime-bid-for-hesc-biz.html

Posted in Stem Cells, Stem Cell Therapy | Comments Off on Geron Weighs Biotime Bid for hESC Biz

Biotime-Geron Deal Attracts Interest from Brit Investor

Posted: November 4, 2012 at 8:00 am


A British investment trust that has
invested in Geron says it is going to take an advantage of an offer
by an Alameda firm that is seeking to acquire Geron's human embryonic
stem cell assets.

Jonathan C. Woolf, managing director
of British & American Investment Trust PLC, said last week in a letter to its
shareholders that it is disappointed in Geron's performance and the abandonment of its hESC program last November. The sudden halt to the
program and its historic clinical trial also surprised the California
stem cell agency, which had loaned Geron $25 million just a few
months earlier. The agency has expressed an interest in continuing the trial.
Woolf said,

“We have been highly critical of
Geron management's decisions and strategy over the past 20 months, in
particular the decision in November 2011 to abruptly exit Geron's
regenerative medicine (stem cell) business in which it was the
acknowledged world leader. Since that time, Geron management has
attempted to sell or partner this business but to date has been
unable to announce any progress on this.”

Woolf's trust is not listed as a major
Geron shareholder by Morningstar, but Woolf said 17 percent of his firm's
investments are in the Menlo Park, Ca., company. The
specific size of the trust's holdings in Geron was not immediately
known.
Woolf pointed to the offer by Biotime,
Inc., of Alameda, Ca., as a way for Geron shareholders to benefit. On
Oct. 18, Biotime proposed a complicated deal in which it would
acquire Geron's hESC program. Biotime's president, Michael West,
founded Geron in 1990. The head of the Biotime subsidiary that would acquire
the Geron assets is Tom Okarma, who was CEO of Geron from 1999 to 2011. (Here are links to brief stories on the offer: Fiercebiotech, New Scientist.)
In his letter, Woolf noted Geron's
declining stock performance. He said he is “seriously concerned”
that Geron has failed to find a buyer for the assets. Woolf said,

“These now dormant and untended
assets are inevitably losing value as competitors make progress in
Geron's absence from the field and patent protection periods
decline.”

Woolf continued,

“We believe BioTime's proposals would
make Geron's stem cell assets in combination with those of BioTime
once again the world's leading stem cell business with sufficient
resources to recommence the discontinued programmes and develop the
business further into the medium term.”

Woolf urged Geron directors and other
Geron shareholders to work with Biotime to complete the deal. Geron
has not commented on the offer.

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/va_Yea0dbF8/biotime-geron-deal-attracts-interest.html

Posted in Stem Cells, Stem Cell Therapy | Comments Off on Biotime-Geron Deal Attracts Interest from Brit Investor

GEN's "Cellular Therapy Wave Finally Cresting". An overview and data set.

Posted: November 4, 2012 at 8:00 am


We first provided a listing (with very few details) of industry-sponsored late-stage (pivotal, phase 3 and 2/3) cell therapy clinical trials on this blog late last year (see the posting here).

We are now pleased to we have worked with Genetic Engineering and Biotechnology News and Enal Razvi of Select Biosciences to provide an updated (as of June 2012) and more detailed listing of industry-sponsored late-stage (pivotal, phase 3 and 2/3) cell therapy clinical trials (excluding cell-based immunotherapies which we intend to cover in a follow-up article).

A link to the listing can be found in an article published today entitled "Cellular Therapy Wave Finally Cresting" found in the November 1, 2012 issue of GEN.  

While not my favorite title, the article is a brief - but we hope useful - overview of the sector and its pipeline.  It also provides a snapshot of the cell therapy products already in commercial distribution. 
Some will quibble about the numbers. Certainly others have published larger revenue numbers, for instance, but in our view these have almost always included revenue from cord blood banking which we have excluded.
We encourage you to read the article but for convenience here is a direct link to the spreadsheet.  Of course it's already out-dated but we'll do an update again soon here on this blog.


Hope this is useful.
--Lee


Source:
http://feedproxy.google.com/~r/CellTherapyBlog/~3/ctijFXeY01M/gens-cellular-therapy-wave-finally.html

Posted in Regenerative Medicine | Comments Off on GEN's "Cellular Therapy Wave Finally Cresting". An overview and data set.

Study of California Stem Agency Likely to be Released in About a Month

Posted: November 4, 2012 at 7:59 am


The $700,000, Institute of Medicine performance study of the $3 billion California stem cell agency is expected to be
released in late November or early December, the IOM said today.

In response to a question last week
from the California Stem Cell Report, Christine Stencel, senior media
relations officer for the IOM in Washington, D.C., briefly discussed
the release plans and the impact of the East Coast super-storm.
Here is the text of her response:

“The DC area escaped the worst of
Sandy’s thumping but nonetheless our schedules and planning have
been somewhat thrown off as we’re playing catch up after two days
of being shut down and some of our committee members and reviewers
are in the areas that got the brunt of the storm. We’re not sure
whether the storm will cause any delays in peer review, but we’re
working toward the goal of publicly releasing the report in late
November or early December. The study staff is working with committee
members to determine the best release format but I anticipate there
will be a press briefing. I’ll send a media advisory when we’ve
got all the details worked out.”

The stem cell agency is paying for the
report, which is examining the performance of the agency. The IOM
began its work in the summer of 2011.

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/iNEFrnWvUO0/study-of-california-stem-agency-likely.html

Posted in Stem Cells, Stem Cell Therapy | Comments Off on Study of California Stem Agency Likely to be Released in About a Month

Geron Weighs Biotime Bid for hESC Biz

Posted: November 4, 2012 at 7:59 am


Geron, Inc., of Menlo Park, Ca., said
today it is assessing an offer by two of its former executives to buy
the human embryonic stem cell program that it abandoned nearly a year
ago.
Geron startled the stem cell world,
including the $3 billion California stem cell agency, when it
jettisoned the first clinical trial of an hESC therapy for financial
reasons. The agency had loaned the company $25 million just a few
months earlier. Geron repaid the loan with interest.
Geron has been mum until today about the Oct. 18 offer by Biotime, Inc., of Alameda, Ca., which is headed
by Michael West, who founded Geron in 1990. Tom Okarma, president of
Geron from 1999 to 2011, is involved with West on the deal and is now
working at Biotime.
Geron's remarks came during a
conference call on its third quarter earnings. A spokesman said the
company is working with Biotime to “assess the feasibility” of
the proposal. He said the proposed transaction is complex and the
company is seeking “additional important details.”
The spokesman declined to offer any
additional comments on the Biotime proposal when questioned following
his initial statement.  
See here and here for earlier stories on the California Stem Cell Report on the Biotime offer. 

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/4JnJvoKwHpA/geron-weighs-biotime-bid-for-hesc-biz.html

Posted in Stem Cells, Stem Cell Therapy | Comments Off on Geron Weighs Biotime Bid for hESC Biz

Biotime-Geron Deal Attracts Interest from Brit Investor

Posted: November 4, 2012 at 7:59 am


A British investment trust that has
invested in Geron says it is going to take an advantage of an offer
by an Alameda firm that is seeking to acquire Geron's human embryonic
stem cell assets.

Jonathan C. Woolf, managing director
of British & American Investment Trust PLC, said last week in a letter to its
shareholders that it is disappointed in Geron's performance and the abandonment of its hESC program last November. The sudden halt to the
program and its historic clinical trial also surprised the California
stem cell agency, which had loaned Geron $25 million just a few
months earlier. The agency has expressed an interest in continuing the trial.
Woolf said,

“We have been highly critical of
Geron management's decisions and strategy over the past 20 months, in
particular the decision in November 2011 to abruptly exit Geron's
regenerative medicine (stem cell) business in which it was the
acknowledged world leader. Since that time, Geron management has
attempted to sell or partner this business but to date has been
unable to announce any progress on this.”

Woolf's trust is not listed as a major
Geron shareholder by Morningstar, but Woolf said 17 percent of his firm's
investments are in the Menlo Park, Ca., company. The
specific size of the trust's holdings in Geron was not immediately
known.
Woolf pointed to the offer by Biotime,
Inc., of Alameda, Ca., as a way for Geron shareholders to benefit. On
Oct. 18, Biotime proposed a complicated deal in which it would
acquire Geron's hESC program. Biotime's president, Michael West,
founded Geron in 1990. The head of the Biotime subsidiary that would acquire
the Geron assets is Tom Okarma, who was CEO of Geron from 1999 to 2011. (Here are links to brief stories on the offer: Fiercebiotech, New Scientist.)
In his letter, Woolf noted Geron's
declining stock performance. He said he is “seriously concerned”
that Geron has failed to find a buyer for the assets. Woolf said,

“These now dormant and untended
assets are inevitably losing value as competitors make progress in
Geron's absence from the field and patent protection periods
decline.”

Woolf continued,

“We believe BioTime's proposals would
make Geron's stem cell assets in combination with those of BioTime
once again the world's leading stem cell business with sufficient
resources to recommence the discontinued programmes and develop the
business further into the medium term.”

Woolf urged Geron directors and other
Geron shareholders to work with Biotime to complete the deal. Geron
has not commented on the offer.

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/va_Yea0dbF8/biotime-geron-deal-attracts-interest.html

Posted in Stem Cells, Stem Cell Therapy | Comments Off on Biotime-Geron Deal Attracts Interest from Brit Investor

umbilical cord | Human Umbilical Cord Blood as a Source of Transplantable Progenitor Cells – Video

Posted: November 4, 2012 at 3:45 am


umbilical cord | Human Umbilical Cord Blood as a Source of Transplantable Progenitor Cells
http://www.cordbloodrecommendation.com How about becoming your own donor? Then, you can always get a perfect match and reduce the risk of rejection to a great extent. To obtain the best possible stem cells, it is advisable to include them in the umbilical cord blood. It is basically the cancer of the blood and marrow, and leads to a reduction of white blood cells in the body. The key is to catch the disease early enough to prevent the loss of critical brain function. The second is a private bank. Your baby could end up getting one of these terrible diseases, and for just pennies a day - less than you spend on pizza in a year - you can stop your baby from coming down with one of these horrible diseases to begin with. Most cord blood banks offer dramatically reduced rates--or even free storage--if your new baby or another child is thought to need a transplant immediately. Nevertheless, it cannot measure the severity of these disorders although it can accurately identify them. While there is still much research to be done, the advancements are profound and important and will continue to proceed at a rapid pace. How Can I Save My Baby #39;s Cord Blood?You can save it by storing it in a private cord blood bank, but if you do not save it, it will be discarded after birth. When the cord is cut, there is still blood inside which is extracted by the doctors. Contact the facility prior to childbirth; they will provide you with a collection kit that you #39;ll need to take to the hospital with you ...From:Implantes DentalesViews:0 0ratingsTime:01:31More inTravel Events

View post:
umbilical cord | Human Umbilical Cord Blood as a Source of Transplantable Progenitor Cells - Video

Posted in Stem Cell Videos | Comments Off on umbilical cord | Human Umbilical Cord Blood as a Source of Transplantable Progenitor Cells – Video

Human Cell Transformation – Video

Posted: November 4, 2012 at 3:45 am


Human Cell Transformation
ll4.me Human Cell Transformation From the contents: Nuclear Barrier Hypothesis of Aging as Mechanism for Tradeoff Growth to Survival.- Establishment of Cell Lines from the Human Middle and Inner Ear Epithelial Cells.- Cellular Systems for Studying Human Oral Squamous Cell Carcinomas.- Heterotopic Ossification Following Musculoskeletal Trauma: Modeling Stem and Progenitor Cells in Their Microenvironment.- Comparative Proteomic Analysis of Mesenchymal Stem Cells Derived from Human Bone Marrow, Umbilical Cord, and Placenta: Implication in the Migration.- Novel Human Prostate Epithelial Cell Culture Models for the Study of Carcinogenesis and of Normal Stem Cells and Cancer Stem Cells.- Prostate Tumor Cell Plasticity: A Consequence of the Microenvironment.- Role of Epigenetics in Cancer Initiation and Progression.- Cancer Stem Cells, Models of Study and Implications of Therapy Resistance Mechanisms.- The Role of the Basal Stem Cell of the Human Breast in Normal Development and Cancer.- Breast Cancer Subtypes: Two Decades of Journey from Cell Culture to Patients.- Parathyroid Hormone Related Protein (PTHrP) in Tumor Progression.- Mechanism of Radiation Carcinogenesis: Role of the TGFBI Gene and The Inflammatory Signalling Cascade.- Histone Deacetylase Inhibitors: Anti-Neoplastic Agent and Radiation Modulator.- Human Fibroblasts for Large-Scale Omics Investigations of ATM Gene Function.- Malignant Transformation of Human Skin Fibroblasts by Two Alternative Pathways.- A Novel ...From:reneebolles4785Views:1 0ratingsTime:00:12More inPeople Blogs

Read the rest here:
Human Cell Transformation - Video

Posted in Stem Cell Videos | Comments Off on Human Cell Transformation – Video

Page 2,575«..1020..2,5742,5752,5762,577..2,5802,590..»